Nuvectis Pharma Inc (NVCT) Live Share Price, Invest From India

Nuvectis Pharma Inc Stock Performance

as on March 17, 2026 at 6:59 am IST

Day's Low
Day's High
$8.90
Day's Price Range
$9.29
$8.99
1.00%
Downside
3.34%
Upside
52 Week's Low
52 Week's High
$5.55
52-Week Price Range
$11.52
$8.99
38.26%
Downside
28.14%
Upside

Nuvectis Pharma Inc share price movements today

Previous Close: $9.03
Open: $9.10
Volume: 515.2K
Day's Low - High: $8.90 - $9.29
52 Week Low - High: $5.55 - $11.52

Nuvectis Pharma Inc Historical Returns

1 Month Return: + 3.08 %
3 Month Return: + 17.43 %
1 Year Return: + 2.03 %
3 Year Return: -20.16 %
5 Year Return: 0 %

Nuvectis Pharma Inc Stock Fundamentals & Key Indicators

Check Nuvectis Pharma Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$239.2M

EPS (TTM)

-1.266

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-188.03%

Nuvectis Pharma Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Nuvectis Pharma Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Nuvectis Pharma Inc	BUY	$239.2M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$41.6B	117.98%	135.09	8.45%
Vertex Pharmaceuticals Incorporated	BUY	$119.2B	114.32%	30.68	32.94%
Beone Medicines Ltd	NA	$32.8B	NA	115	5.37%
Regeneron Pharmaceuticals, Inc.	BUY	$78.8B	54.67%	17.99	31.41%

Stock Returns calculator for Nuvectis Pharma Inc Stock including INR - Dollar returns

The Nuvectis Pharma Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Nuvectis Pharma Inc investment value today

Current value as on today

₹1,08,081

Returns

₹8,081

(+8.08%)

Returns from Nuvectis Pharma Inc Stock

₹1,582 (+1.58%)

Dollar Returns*

₹6,499 (+6.5%)

Analyst Recommendation on Nuvectis Pharma Inc Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Nuvectis Pharma Inc. Average target price of $16.8

Nuvectis Pharma Inc Share Price Target

Get share price movements and forecasts by analysts on Nuvectis Pharma Inc.

What analysts predicted

46.49%UPSIDE

Target Price

$16.8

Current Price

$8.99

Analyzed by

9 Analysts

Target

$16.80

Nuvectis Pharma Inc target price $16.8, a slight upside of 46.49% compared to current price of $8.99. According to 9 analysts rating.

Nuvectis Pharma Inc Stock’s Investor Sentiment and Interest

Search interest for Nuvectis Pharma Inc Stock has increased by 6% in the last 30 days, reflecting an upward trend in search activity.

Time period: February 15, 2026 to March 17, 2026

Change:6% versus previous 30 day period

Nuvectis Pharma Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	-4	-	-	-	26	-	-	-	-
Gross Profit	-6	-15	-4	-4	-4	13	-	-	-	-
Operating Income	-6	-6	-4	-4	-4	-6	-5	-6	-7	-7
EBITDA	-6	-6	-4	-4	-4	-6	-5	-6	-7	-8
Interest Expense	-	0	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-5	-6	-4	-4	-4	-6	-5	-6	-7	-7
Income Tax Expense	6	0	0	-	-	-	-	-	-	-
Net Income	-5	-6	-4	-4	-4	-6	-5	-6	-7	-7
Net Profit Margin	0.00%	161.47%	0.00%	0.00%	0.00%	-23.32%	0.00%	0.00%	0.00%	0.00%

Nuvectis Pharma Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	0	-	-	-
Gross Profit	-12	-19	-22	-	-
Operating Income	-12	-19	-22	-19	-27
EBITDA	-12	-18	-22	-19	-27
Interest Expense	0	0	-	-	-
Depreciation	-	-	-	-	-
Income Before Tax	-12	-19	-22	-19	-26
Income Tax Expense	0	0	0	-19	-
Net Income	-12	-18	-22	-19	-26
Net Profit Margin	0.00%	-12608.72%	0.00%	0.00%	0.00%

Nuvectis Pharma Inc Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-6	-4	-4	-4	-6	-5	-6	-9	-7
Operating Cash Flow	-3	-4	-3	-2	-2	-4	-3	-4	-3
Investing Cash Flow	-	-	-	-	-	-	-	-	-
Financing Cash Flow	0	4	1	1	3	15	0	13	0
Change in Cash	-2	0	-1	0	1	11	-3	8	-3

Nuvectis Pharma Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-12	-19	-22	-19	-26
Operating Cash Flow	-9	-13	-15	-12	-16
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	15	27	15	11	29
Change in Cash	5	14	0	0	13

Global Institutional Holdings in Nuvectis Pharma Inc

Funds	Holdings
Northern Trust Corp	0.4%
Royal Bank of Canada	0.12%
Vanguard Group Inc	3.19%
BlackRock Inc	2.59%
Baldwin Brothers Inc	1.47%

See all

Insights on Nuvectis Pharma Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 6 months, NVCT stock has moved up by 45.4%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 65.2% return, outperforming this stock by 85.4%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 29.6% return, outperforming this stock by 27.6%

About Nuvectis Pharma Inc

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.

Organisation	Nuvectis Pharma Inc
Headquarters	1 Bridge Plaza, Fort Lee, NJ, United States, 07024
CEO	Mr. Ron Bentsur M.B.A.
E-voting on shares	Click here to vote

Key Management of Nuvectis Pharma Inc

Name	Title
Mr. Ron Bentsur M.B.A.	Co-Founder, Chairman, CEO & President
Dr. Enrique Poradosu Ph.D.	Co-Founder, Executive VP, Chief Scientific & Business Officer
Mr. Shay Shemesh	Co-Founder, Executive VP, Chief Development & Operations Officer
Mr. Michael Carson CPA	Vice President of Finance

FAQs

What is Nuvectis Pharma Inc share price today?

Nuvectis Pharma Inc share price today is $8.99 as on March 17, 2026 at 1:29 am IST at the close of the market. Nuvectis Pharma Inc share today touched a day high of $9.29 and a low of $8.9.

What is the 52 week high and 52 week low for Nuvectis Pharma Inc share?

Nuvectis Pharma Inc share touched a 52 week high of $11.52 on April 28, 2025 and a 52 week low of $5.55 on November 7, 2025. Nuvectis Pharma Inc stock price today i.e. March 17, 2026 at 1:29 am IST is closed at $8.99,which is 21.96% down from its 52 week high and 61.98% up from its 52 week low.

What is Nuvectis Pharma Inc's market capitalisation today?

Nuvectis Pharma Inc market capitalisation is $0.00T as on March 17, 2026 at 1:29 am IST.

How to invest in Nuvectis Pharma Inc Stock (NVCT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Nuvectis Pharma Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Nuvectis Pharma Inc Shares that will get you 0.1669 shares as per Nuvectis Pharma Inc share price of $8.99 per share as on March 17, 2026 at 1:29 am IST.

What is the minimum amount required to buy Nuvectis Pharma Inc Stock (NVCT) from India?

Indian investors can start investing in Nuvectis Pharma Inc (NVCT) shares with as little as ₹92.335 or $1 (as of March 17, 2026 at 2:40 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹923.35 in Nuvectis Pharma Inc stock (as per the Rupee-Dollar exchange rate as on March 17, 2026 at 2:40 am IST). Based on Nuvectis Pharma Inc share’s latest price of $8.99 as on March 17, 2026 at 1:29 am IST, you will get 1.1123 shares of Nuvectis Pharma Inc. Learn more about fractional shares .